© Credit: Andrew Loxley, courtesy of the International Partnership for Microbicides
Post written by Tishina Okegbe, FHI 360
On December 11, 2019, Amneal Pharmaceuticals received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) to launch its generic vaginal ring, EluRyng™ with active ingredients, etonogestrel, a progestin, and ethinyl estradiol, an estrogen. This is the first generic version of the NuvaRing® vaginal ring, which is manufactured by Merck.
The vaginal ring is a user-controlled method that provides one month of pregnancy protection. A ring is inserted in the vagina and remains in place continuously for three weeks. After removal, a withdrawal bleed occurs, and a new ring can be inserted one week after the last ring was removed.
To find out more information about the EluRyng™ visit amneal.com.